LUKE TREGILGAS
Associate, UK and European Patent Attorney, Haley Guiliano LLP, London, United Kingdom

Abstract

This article explores the evolving patent landscape at the intersection of biotechnology, pharmaceuticals, and artificial intelligence (AI), focusing on the impacts of AI on patentability and enforcement within UK and European patent law. As AI becomes increasingly integrated into biotech and pharma innovations, it introduces new complexities that can affect patent grant rates and enforceability, potentially deterring ongoing investment. The article discusses key challenges, including subject matter exclusions, the rigorous examination process, and the implications for future innovation. It also highlights the importance of adapting patent strategies to secure the necessary protection for AI-driven advancements in these critical sectors.

THE EVOLVING PATENT LANDSCAPE AT THE INTERSECTION OF BIOTECHNOLOGY, PHARMACEUTICALS, AND ARTIFICIAL INTELLIGENCE
The rapid evolution of artificial intelligence (AI) is reshaping numerous industries, with biotechnology and pharmaceuticals at the forefront of this transformation. As AI becomes increasingly integrated into these fields, it presents both opportunities and challenges from a patent law perspective, particularly within the frameworks of UK and European patent law. This article explores the evolving patent landscape at the intersection of biotechnology, pharmaceuticals, and AI, focusing on the potential implications of AI on patentability, and on enforcement of granted patent rights.

THE CONFLUENCE OF AI, BIOTECHNOLOGY, AND PHARMACEUTICALS

Biotechnology and pharmaceuticals have long been fields driven by innovation, with patents serving as critical tools for protecting new inventions and fostering further research and development. In recent years, AI has emerged as a powerful tool within these industries, aiding in drug discovery, patient diagnosis, treatment planning, and the prediction of molecula ...